The CJC-1295 research record: a few precise human studies, a halted program

Mechanism: a long-acting GHRH analog at the pituitary

CJC-1295 binds the GHRH receptor on anterior-pituitary somatotrophs, activating Gs/cAMP/PKA signaling that drives synthesis and pulsatile release of growth hormone, which in turn raises hepatic IGF-1 ^[2]. Four protease-resistant substitutions plus — in the DAC variant — covalent binding to serum albumin give the molecule a multi-day half-life, so a single dose elevates GH and IGF-1 for days while preserving the pulsatile pattern of GH secretion ^[1].

The original rat work established the chemistry. A series of hGRF(1-29) analogs bearing a C-terminal maleimidopropionyl-lysine handle were screened; the lead, CJC-1295, combined four DPP-IV-protective substitutions with covalent bioconjugation to circulating serum albumin and showed a 4-fold increase in GH area-under-the-curve over two hours versus unconjugated hGRF(1-29), with peptide detectable in plasma beyond 72 hours and enhanced in vitro stability against dipeptidylpeptidase-IV ^[2]. The mechanism is, structurally, a clearance problem solved twice — once with substitutions, once with an albumin anchor.

What the published human research on CJC-1295 actually shows

<a id="human-research"></a>

What the Published Human Research on CJC-1295 Actually Shows

The peer-reviewed human dataset is limited to early-phase studies. Teichman 2006 established the pharmacokinetics in healthy adults; Ionescu and Frohman 2006 characterized the GH and IGF-1 response and showed pulsatility was preserved; and a 2009 proteomic study found reproducible serum-protein changes that correlated with IGF-1 ^[1][3][5]. There is no large efficacy or long-term safety trial.

Reported Outcomes in Human and Animal Studies

<a id="reported-outcomes"></a>

In healthy men aged 20-40, a single subcutaneous dose of CJC-1295 (60 or 90 ug/kg) raised trough/basal GH approximately 7.5-fold and mean GH by about 46% and IGF-1 by about 45% one week later, while the frequency and magnitude of pulsatile GH secretion were unaltered ^[3]. In healthy adults aged 21-61, single 30 or 60 ug/kg doses produced 2- to 10-fold GH increases for six days or more; after multiple doses IGF-1 remained above baseline up to 28 days ^[1]. In GHRH-knockout mice, once-daily 2 ug CJC-1295 fully normalized body weight and length and increased pituitary GH mRNA ^[4].

What the research reports about CJC-1295 effects

<a id="reported-effects"></a>

The reported effects of CJC-1295 are biomarker effects: it raises growth hormone and, downstream, IGF-1 ^[3]. A 2009 proteomic study in 11 healthy young men found CJC-1295 shifted the serum proteome — decreasing apolipoprotein A1 and a transthyretin isoform and increasing a C-terminal albumin fragment and immunoglobulin species — with the immunoglobulin/albumin-fragment signal correlating linearly with IGF-1, identifying candidate biomarkers of GH/IGF-1 axis activation ^[5].

A single GH-secretagogue study in hypogonadal men reported raised serum IGF-1, an example of secretagogue-class effects on the GH/IGF-1 axis in a specific population ^[9]. Beyond these biomarker changes, downstream clinical outcomes — body composition, recovery, anti-aging endpoints — are not established for CJC-1295 in controlled trials. The record reports what GH and IGF-1 did, not what those changes produced over time.

Why the CJC-1295 Phase 2 trial was halted

<a id="phase-2-halted"></a>

Why the CJC-1295 Phase 2 Trial Was Halted

ConjuChem's Phase 2 trial of CJC-1295 DAC in HIV-associated visceral obesity (NCT00267527) was discontinued and the long-acting DAC program did not advance ^[7]. A patient death during the development era is frequently cited in connection with the halt, though a causal link to CJC-1295 was not established in the public record ^[7]. The DAC analog has not returned to clinical development since.

The peptide also has a parallel life in analytical chemistry. CJC-1295 was structurally identified by high-resolution LC-MS/MS as the active ingredient in an unknown 'GHRH' pharmaceutical preparation seized in an anti-doping context — a definitive identification of the compound in a black-market product ^[6]. CJC-1295 is prohibited at all times in sport under WADA Section S2.

CJC-1295 among GHRH analogs (sermorelin, tesamorelin)

<a id="analog-class"></a>

CJC-1295 Among GHRH Analogs (Sermorelin, Tesamorelin)

CJC-1295 sits in a class of GHRH analogs that includes sermorelin (a GHRH(1-29) analog) and tesamorelin, an FDA-approved GHRH analog for HIV-associated lipodystrophy and the closest approved-drug comparator ^[12]. The 2025 Nature Reviews Endocrinology review describes the receptor signaling and the rationale for long-acting analog design across this family ^[12]. The defining difference within the class is duration and regulatory status: tesamorelin is approved and shorter-acting; CJC-1295 DAC is unapproved and engineered to last days. CJC-1295 versus sermorelin comes down to the same axes — both act at the GHRH receptor, but sermorelin is short-acting and CJC-1295 DAC carries the albumin anchor.

CJC-1295 and Ipamorelin: The Two-Receptor Rationale

<a id="cjc-1295-ipamorelin"></a>

GHRH analogs and growth-hormone-releasing peptides act through distinct receptors and synergize, producing GH release greater than the sum of either alone ^[13]. Ipamorelin is a selective GH secretagogue that releases GH with minimal effect on ACTH/cortisol or prolactin; its GH-releasing potency and exposure-response have been modeled in swine ^[14], and the GHRP class has shown effects beyond acute GH release — ipamorelin counteracted glucocorticoid-induced decreases in bone formation in a rodent model ^[15]. This two-receptor model is the mechanistic basis for pairing CJC-1295 and ipamorelin, although no controlled human efficacy trial of the specific combination in healthy adults exists. A 2013 study showed distinct secretagogues exert differential control over pulsatile GH secretion ^[11], and a 2011 GHRH-analog study reported effects on GH pulsatility and insulin sensitivity ^[10] — both inform how layered GH-axis stimulation is interpreted.